Drive-Through Screening Center for COVID-19: a Safe and Efficient Screening System against Massive Community Outbreak
暂无分享,去创建一个
Jin Yong Kim | M. Sung | K. Kwon | Ki Tae Kwon | Jae Hoon Ko | Heejun Shin | Minki Sung | J. Ko | Heejun Shin | J. Y. Kim
[1] C. Dolea,et al. World Health Organization , 1949, International Organization.
[2] A. Cassone,et al. Effects of chloroquine on viral infections: an old drug against today's diseases , 2003, The Lancet Infectious Diseases.
[3] M. Petri,et al. Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines , 2018, Arthritis Research & Therapy.
[4] Jianjun Gao,et al. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.
[5] J. Chu,et al. An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease. , 2018, Antiviral research.
[6] K. Rainsford,et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases , 2015, Inflammopharmacology.
[7] Report on the Epidemiological Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from January 19 to March 2, 2020 , 2020, Journal of Korean medical science.
[8] L. Sehulster,et al. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). , 2003, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[9] D. Plantone,et al. Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review , 2018, Clinical Drug Investigation.
[10] Philippe Colson,et al. Chloroquine for the 2019 novel coronavirus SARS-CoV-2 , 2020, International Journal of Antimicrobial Agents.
[11] Jae-Won Park,et al. Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by Plasmodium vivax , 2009, Antimicrobial Agents and Chemotherapy.
[12] Gregory H. Gilbert,et al. Drive-through medicine: a novel proposal for rapid evaluation of patients during an influenza pandemic. , 2010, Annals of emergency medicine.
[13] David Willauer,et al. Mass prophylaxis dispensing concerns: traffic and public access to PODs. , 2011, Biosecurity and bioterrorism : biodefense strategy, practice, and science.
[14] Lewis J Radonovich,et al. Respirator tolerance in health care workers. , 2009, JAMA.
[15] Sumiko Mekaru,et al. Open access epidemiological data from the COVID-19 outbreak , 2020, The Lancet Infectious Diseases.